Skip to content

Alto Neuroscience ANRO Enterprise value

Enterprise value at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$5.01B+104%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$3.56B+36.6%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$1.43B+352%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$8.44B+1,309%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$696.49M+26.9%
LBR
LB Pharmaceuticals Inc Common StockLBRX
$389.92M

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$874.19M+1,335%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Calculated from Alto Neuroscience’s reported figures.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's enterprise value?
Alto Neuroscience (ANRO) reported enterprise value of $474.75M in Q1 2026.
How has Alto Neuroscience's enterprise value changed year-over-year?
Alto Neuroscience's enterprise value increased by 712.2% year-over-year, from -$77.55M to $474.75M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.